Work

The Clone Ranger?

Year: 2008

Type: article

Abstract: A recent article describing a T-lymphocyte cell clone that eliminated melanoma in a patient with advanced metastatic disease1 excited an exceptionally high level of publicity worldwide. An accompanying Perspective in the New England Journal of Medicine breathlessly concluded that for cell therapy of cancer, “the endgame has begun.”2 Such broad enthusiasm for an article on a T-cell clone seems largely based on a hoped-for analogy to the development of monoclonal antibodies, which clearly opened a new era in immunotherapy.

Source: Molecular Therapy

DOI: 10.1038/mt.2008.154

Authors: Helen E Heslop, Malcolm K Brenner

Institutions: Houston Methodist, Baylor College of Medicine, Texas Children's Hospital

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,500